H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Ocugen (OCGN) to $10 from $7 and keeps a Buy rating on the shares. The firm cites the Phase 2 ArMaDa results and the program’s progress into late-stage evaluation for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen Reports Positive Phase 2 Data for OCU410 Therapy
- Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
- Ocugen announces 12-month data from ArMaDa clinical trial of OCU410
- TTD, OCGN, STZ, VRTX, LCID Trending With Analysts
- Ocugen Gains $15 Million, Extends Cash Runway to 2027